A large region (approximately equal to 95 kDa) of human factor VIII is dispensable for in vitro procoagulant activity.
Factor VIII (antihemophilic factor) is a high molecular weight plasma glycoprotein that participates in the blood clotting cascade. The recent cloning and sequence analysis of the cDNA encoding human factor VIII revealed an obvious domain structure for the protein, which can be represented as A1-A2-B-A3-C1-C2. We now report the DNA sequence analysis of porcine exons encoding the entire B domain and part of the A2 and A3 domains. We found an unusually high degree of porcine-human amino acid sequence divergence in the B region compared with the limited sequence available for other regions of the porcine factor VIII molecule. In addition to sequence divergence, there are numerous gaps in the porcine B domain totalling over 200 amino acids. Recombinant DNA techniques were used to effect the removal of large segments of DNA encoding the B domain from the full-length human factor VIII cDNA. These constructs directed the synthesis of biologically active factor VIII when introduced into mammalian cells despite the deletion of up to 38% of the factor VIII molecule.
D000595:Amino Acid Sequence; D001483:Base Sequence; D005075:Biological Evolution; D001777:Blood Coagulation; D004262:DNA Restriction Enzymes; D005169:Factor VIII / Q000235:genetics* / Q000378:metabolism; D005796:Genes; D006801:Humans; D008970:Molecular Weight; D010957:Plasmids
D005169:Factor VIII; D004262:DNA Restriction Enzymes